{
    "clinical_study": {
        "@rank": "129331", 
        "arm_group": {
            "arm_group_label": "LDE225", 
            "arm_group_type": "Experimental", 
            "description": "LDE225"
        }, 
        "brief_summary": {
            "textblock": "This study is to evaluate the pharmacokinetics and safety of 800 mg of LDE225 in subjects\n      with impaired hepatic function and healthy subjects with normal hepatic function."
        }, 
        "brief_title": "Effect of Hepatic Impairment on LDE225..", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Normal Hepatic Function,", 
            "Impaired Hepatic Function"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria (all groups):\n\n          -  Male and sterile or postmenopausal female age \u226518 to \u226470 years old.\n\n          -  Normal Vital signs\n\n        Inclusion (group mild, moderate and severe hepatic impairment):\n\n        -Subjects with confirmed cirrhosis\n\n        Exclusion (all groups):\n\n          -  Woman of childbearing potential and pregnant or lactating females or male not using\n             condom\n\n          -  Risk factors for torsades de pointes\n\n          -  Clinically significant cardio-vascular disease\n\n          -  severe or uncontrolled medical conditions\n\n          -  Smokers consuming greater than 10 cigarettes or equivalent nicotine containing\n             products per day.\n\n          -  Use of investigational drugs (i.e. participation in any clinical investigation)\n\n        Exclusion for moderate, mild and severe groups:\n\n          -  Symptoms or history of encephalopathy\n\n          -  Clinical evidence of severe ascites\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01764776", 
            "org_study_id": "CLDE225A2113"
        }, 
        "intervention": {
            "arm_group_label": "LDE225", 
            "description": "LDE225", 
            "intervention_name": "LDE225", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "LDE225,", 
            "Pharmacokinetics,", 
            "PK,", 
            "Postmenopausal women,", 
            "normal hepatic function,", 
            "mild hepatic impairment,", 
            "moderate hepatic impairment,", 
            "severe hepatic impairment"
        ], 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "contact": {
                    "phone": "305-243-5930"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33136"
                    }, 
                    "name": "University of Miami Div. of Clinical Pharmacology"
                }, 
                "investigator": {
                    "last_name": "Richard A. Preston", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria", 
                        "zip": "1612"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tel-Aviv", 
                        "country": "Israel", 
                        "zip": "64239"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Troitsk", 
                        "country": "Russian Federation", 
                        "state": "Russia", 
                        "zip": "142190"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation", 
                        "zip": "117198"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Withdrawn"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Bulgaria", 
                "Germany", 
                "Israel", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period", 
                "measure": "LDE225A pharmacokinetic parameter Tmax", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period", 
                "measure": "LDE225A pharmacokinetic parameter Cmax", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period", 
                "measure": "LDE225A pharmacokinetic parameter AUClast", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period", 
                "measure": "LDE225A pharmacokinetic parameter AUCinf", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Evaluate the pharmacokinetics of a single dose of LDE225 in subjects with impaired hepatic function as compared to healthy subjects for an 8 weeks follow up period", 
                "measure": "LDE225A pharmacokinetic parameter  T1/2", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01764776"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Laboratory assessments", 
                "measure": "Occurrence of abnormal safety laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Plasma protein binding of LDE225", 
                "measure": "Plasma protein binding of LDE225", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "ECGs", 
                "measure": "Occurrence of changes in ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "follow up on any adverse event", 
                "measure": "Occurrence of  adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}